Identification | More | [Name]
2,2-Dimethylbutyric acid | [CAS]
595-37-9 | [Synonyms]
2,2'-DIMETHYL BUTANOIC ACID 2,2-DIMETHYLBUTANOIC ACID 2,2-DIMETHYLBUTYRIC ACID 2,2-DIMETHYL-N-BUTYRIC ACID DIMETHYLETHYLACETIC ACID NEOHEXANOIC ACID 2,2-Dimethylbuttersαure alpha,alpha-Dimethylbutanoic acid alpha,alpha-Dimethylbutyric acid Butanoicacid,2,2-dimethyl- Butyric acid, 2,2-dimethyl- 2,2-Dimethylbutyricacid,97% 2,2-Dimethylbutanoic 2,2-Dimethylbutyric acid ,99% | [EINECS(EC#)]
209-865-0 | [Molecular Formula]
C6H12O2 | [MDL Number]
MFCD00004200 | [Molecular Weight]
116.16 | [MOL File]
595-37-9.mol |
Chemical Properties | Back Directory | [Melting point ]
-14°C | [Boiling point ]
94-96 °C/5 mmHg (lit.) | [density ]
0.928 g/mL at 25 °C(lit.)
| [refractive index ]
n20/D 1.4154(lit.)
| [Fp ]
175 °F
| [storage temp. ]
Refrigerator | [solubility ]
Chloroform (Sparingly), Methanol (Slightly) | [form ]
Liquid | [pka]
pK1:5.03 (18°C) | [color ]
Clear colorless to pale yellow | [Specific Gravity]
0.928 | [Decomposition ]
176-178 ºC | [Detection Methods]
GC,NMR | [BRN ]
1720666 | [InChIKey]
VUAXHMVRKOTJKP-UHFFFAOYSA-N | [CAS DataBase Reference]
595-37-9(CAS DataBase Reference) | [NIST Chemistry Reference]
Butanoic acid, 2,2-dimethyl-(595-37-9) |
Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . S36/37:Wear suitable protective clothing and gloves . S36:Wear suitable protective clothing . | [RIDADR ]
3265 | [WGK Germany ]
3
| [HazardClass ]
8 | [PackingGroup ]
III | [HS Code ]
29156000 |
Hazard Information | Back Directory | [Chemical Properties]
Colorless to light yellow or light green liquid | [Uses]
2,2-Dimethylbutyrate (DMB) is a potential treatment for thalassemia and hemoglobinopathies. | [Definition]
ChEBI: A branched-chain fatty acid and metabolite of the lactone prodrug simvastatin, whose sodium salt is potentially useful for the treatment of thalassaemias and haemoglobinopathies. | [Synthesis Reference(s)]
Synthetic Communications, 19, p. 1945, 1989 DOI: 10.1080/00397918908052587 |
|
|